Amicus Therapeutics Strengthens Executive Leadership Team

Amicus Therapeutics, a biopharmaceutical company that develops therapies for rare and orphan diseases, has strengthened its executive leadership with the appointment of two new senior members of the commercial and executive team.

Mark Baldry, a biopharmaceutical brand strategist with senior-level experience at Biogen and Shire has joined the company as vice president of global marketing.

Willem van Weperen, most recently the former chief commercial officer of Prosensa Holding, has been appointed regional vice president and country manager, international.

Both Mr. Baldry and Mr. van Weperen held the positions of global head of marketing for rare diseases at Shire and Genzyme, respectively.

Additionally, the company has promoted Hung Do to chief science officer.

“Both Mark and Willem have managed several successful launches of new therapies for individuals living with rare diseases, including specifically in Fabry disease,” said John Crowley, chairman and chief executive officer, Amicus Therapeutics. “I am also pleased to announce Hung’s promotion to chief science officer in recognition of his extraordinary scientific knowledge, vision and leadership. Today our Amicus team is stronger than ever as we prepare for the global launch of Galafold, our precision medicine for Fabry disease, as well as the continued advancement of our pipeline.”